Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q2 2016 · 10-Q
Revenue$0.00$0.00derived−100.0% vs Q2 2015 Net Income-$43.20K-$43.20KN/M vs Q2 2015 EPS Diluted-$0.02-$0.02N/M vs Q2 2015 Gross Profitderived$0−100.0%
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,573N/M ended Jun 30, 2016 · filed Aug 30, 2017 · 426 d after period end